CA3134185A1 - Mesenchymal stem cells and uses therefor - Google Patents

Mesenchymal stem cells and uses therefor Download PDF

Info

Publication number
CA3134185A1
CA3134185A1 CA3134185A CA3134185A CA3134185A1 CA 3134185 A1 CA3134185 A1 CA 3134185A1 CA 3134185 A CA3134185 A CA 3134185A CA 3134185 A CA3134185 A CA 3134185A CA 3134185 A1 CA3134185 A1 CA 3134185A1
Authority
CA
Canada
Prior art keywords
mesenchymal stem
stem cells
cells
pharmaceutical composition
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3134185A
Other languages
English (en)
French (fr)
Inventor
Sudeepta Aggarwal
Alla Danilkovitch
Mark F. Pittenger
Timothy Varney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of CA3134185A1 publication Critical patent/CA3134185A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CA3134185A 2007-03-22 2008-03-21 Mesenchymal stem cells and uses therefor Pending CA3134185A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/726,676 US20080095749A1 (en) 2004-03-22 2007-03-22 Mesenchymal stem cells and uses therefor
US11/726,676 2007-03-22
CA2637157A CA2637157C (en) 2007-03-22 2008-03-21 Mesenchymal stem cells and uses therefor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2637157A Division CA2637157C (en) 2007-03-22 2008-03-21 Mesenchymal stem cells and uses therefor

Publications (1)

Publication Number Publication Date
CA3134185A1 true CA3134185A1 (en) 2008-09-21

Family

ID=39735516

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3134185A Pending CA3134185A1 (en) 2007-03-22 2008-03-21 Mesenchymal stem cells and uses therefor
CA2637157A Active CA2637157C (en) 2007-03-22 2008-03-21 Mesenchymal stem cells and uses therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2637157A Active CA2637157C (en) 2007-03-22 2008-03-21 Mesenchymal stem cells and uses therefor

Country Status (10)

Country Link
US (3) US20080095749A1 (enExample)
EP (6) EP3095450B1 (enExample)
JP (2) JP2010522212A (enExample)
KR (7) KR20090122415A (enExample)
CN (1) CN101626772A (enExample)
BR (1) BRPI0802241A2 (enExample)
CA (2) CA3134185A1 (enExample)
DK (1) DK2123747T3 (enExample)
ES (3) ES2891574T3 (enExample)
WO (1) WO2008116157A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005093044A1 (en) 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
DE602005017877D1 (de) * 2004-03-30 2010-01-07 Boston Scient Ltd Restenose-therapie mit mesenchym-stammzellen
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
MX342474B (es) 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
AU2006304277B2 (en) * 2005-10-13 2012-07-05 Celularity Inc. Immunomodulation using placental stem cells
ES2671355T3 (es) 2005-12-29 2018-06-06 Anthrogenesis Corporation Poblaciones de células madre placentarias
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
SI2120977T1 (sl) 2007-02-12 2014-01-31 Anthrogenesis Coroporation Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
US20110150845A1 (en) * 2008-05-02 2011-06-23 Massachusetts Institute Of Technology Methods and compositions for modulating immunological tolerance
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
DK2330889T3 (en) 2008-08-20 2017-01-30 Anthrogenesis Corp Improved cell composition and process for making the same
MX2011001992A (es) 2008-08-22 2011-03-29 Anthrogenesis Corp Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
US20110177015A1 (en) * 2008-10-05 2011-07-21 Hymie Friedlander Skin and hair care using extract from conditioned medium cultured by mesenchymal stem cells and other regenerative cells
CA2743566C (en) 2008-11-19 2021-11-09 Anthrogenesis Corporation Amnion derived adherent cells
AU2010276201B2 (en) * 2009-07-21 2013-10-17 Healios K.K. Use of stem cells to reduce leukocyte extravasation
WO2011070974A1 (ja) * 2009-12-07 2011-06-16 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
CA2784847C (en) * 2009-12-18 2017-11-21 Molly Sandra Shoichet Injectable polymer composition for use as a cell delivery vehicle
AU2011237743A1 (en) 2010-04-08 2012-11-01 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
KR101677293B1 (ko) * 2010-04-16 2016-11-17 서울대학교병원 줄기세포의 활성을 증가시키는 방법 및 상기 방법에 의해 제조된 고활성 줄기 세포
SG10201913920PA (en) 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
CN101991878A (zh) * 2010-11-08 2011-03-30 中国人民解放军军事医学科学院基础医学研究所 由复合msc的plga和msc组成的制剂及其应用
CN101991880A (zh) * 2010-11-08 2011-03-30 中国人民解放军军事医学科学院基础医学研究所 由复合msc的plga/tcp和msc组成的制剂及其应用
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
CA2829586C (en) * 2011-03-11 2021-03-02 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
EP3443968A1 (en) 2011-06-01 2019-02-20 Celularity, Inc. Treatment of pain using placental stem cells
US8961956B2 (en) * 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
TW202537630A (zh) * 2011-11-30 2025-10-01 美商安斯泰來再生醫藥協會 利用血管母細胞產生間葉基質細胞之方法
CN103191154B (zh) * 2012-01-06 2015-09-09 上海交通大学医学院 充质干细胞及其提取方法在制备银屑病的药物中的应用
WO2014098960A2 (en) * 2012-05-16 2014-06-26 The Johns Hopkins University Stem cells as an individualized maternal therapy for prevention of prematurity
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
CA2893942C (en) * 2012-12-12 2023-03-28 Mesoblast, Inc. Treatment of diseases of endothelial dysfunction and inflammation
KR101748712B1 (ko) * 2012-12-12 2017-06-19 메소블라스트, 아이엔씨. 호흡기 질환의 치료 또는 예방 방법
US10357538B2 (en) * 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
EP3613847A1 (en) * 2013-03-13 2020-02-26 The University of Queensland A method of isolating cells for therapy and prophylaxis
IL289870B2 (en) 2013-04-12 2023-03-01 Lafrancesca Saverio Improving organs for transplantation
EP3013943B1 (en) * 2013-06-25 2019-04-10 TiGenix, S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
CN106255884B (zh) * 2013-10-04 2019-01-11 赛尔爱迪尔私人有限公司 用于细胞治疗的生物标志物
JP6210049B2 (ja) 2014-11-04 2017-10-11 トヨタ自動車株式会社 車両
WO2016110565A1 (en) * 2015-01-08 2016-07-14 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat)
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
WO2016170187A2 (en) * 2015-04-24 2016-10-27 Tigenix, S.A.U Biomarkers for determining the clinical response to cell therapy
US11243218B2 (en) 2015-10-07 2022-02-08 Sangui Bio Pty Ltd. Blood preparation and profiling
KR20180102096A (ko) * 2015-12-22 2018-09-14 생귀 바이오 피티와이. 엘티디 에리스로사이트를 사용한 치료 방법
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
CN105769911A (zh) * 2016-03-23 2016-07-20 中国人民解放军第二军医大学 间充质干细胞诱导斑秃处毛发再生的方法及应用
KR101970642B1 (ko) * 2016-04-06 2019-05-17 주식회사 제이제이메이딘 줄기세포 배양용 배지조성물 및 그를 이용한 줄기세포 배양방법
JP7108537B2 (ja) * 2016-04-27 2022-07-28 ロート製薬株式会社 Ｃｄ２０１、ｃｄ４６、ｃｄ５６、ｃｄ１４７及びｃｄ１６５からなる群より選択される少なくとも１種の細胞表面マーカーを発現する間葉系幹細胞及びその調製方法、並びに上記間葉系幹細胞を含む医薬組成物及びその調製方法
WO2018026203A1 (ko) 2016-08-05 2018-02-08 한양대학교 에리카산학협력단 지방 유래 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 폐 섬유증 예방 또는 치료용 조성물
WO2018092769A1 (ja) 2016-11-15 2018-05-24 株式会社カネカ 胎児付属物に由来する間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN106492194A (zh) * 2016-11-30 2017-03-15 广州赛莱拉干细胞科技股份有限公司 一种干细胞外泌体制剂及其制备方法和应用
EP3559253A4 (en) 2016-12-20 2020-08-26 Sangui Bio Pty. Ltd BLOOD PROFILING WITH PROTEASE INHIBITORS
EP3583945A4 (en) * 2017-02-15 2020-11-18 Rohto Pharmaceutical Co., Ltd. PULMONARY FIBROSIS TREATMENT AGENT, PTPRR EXPRESSION PROMOTIONER, AND PULMONARY FIBROSIS TREATMENT KIT
WO2018170335A1 (en) 2017-03-15 2018-09-20 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
AU2018372631B2 (en) 2017-11-22 2025-06-05 Mesoblast International Sarl Cellular compositions and methods of treatment I
JP7454379B2 (ja) 2017-12-28 2024-03-22 株式会社カネカ 接着性幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
CN112566644A (zh) * 2018-07-17 2021-03-26 北京三有利和泽生物科技有限公司 牙源干细胞及其用途
US20220154147A1 (en) * 2019-03-12 2022-05-19 Global Stem Cell Technology Immunomodulating mesenchymal stem cells
US20220175666A1 (en) * 2019-03-21 2022-06-09 Anterogen Co., Ltd. Injection formulation composition containing mesenchymal stem cell-hydrogel and method for preparing, freezing and defrosting same
JP7530893B2 (ja) 2019-06-14 2024-08-08 株式会社カネカ 間葉系細胞を含む細胞集団、それを含む医薬組成物、及び、その製造方法
CN110772537A (zh) * 2019-11-07 2020-02-11 深圳科康干细胞技术有限公司 脐带血间充质干细胞组合物在治疗慢性阻塞性肺疾病中的应用
JP2023517035A (ja) * 2020-03-05 2023-04-21 メゾブラスト・インターナショナル・エスアーエールエル 間葉系統前駆または幹細胞を使用して炎症性肺疾患を治療するための方法
AU2021245369A1 (en) * 2020-04-03 2022-11-03 Mesoblast International Sàrl Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
US20210315937A1 (en) * 2020-04-08 2021-10-14 University Of South Florida Methods of treating inflammation
WO2021226373A2 (en) 2020-05-08 2021-11-11 Gallant Pet, Inc. Uterine-derived regenerative cell compositions and uses thereof
EP3909594A1 (en) * 2020-05-14 2021-11-17 Bernat Soria Escoms Mesenchymal stromal cells for the treatment of covid-19 and other inflammatory, autoimmune and degenerative diseases
CN111568930A (zh) * 2020-05-23 2020-08-25 湖南源品细胞生物科技有限公司 一种msc用于调节nk细胞数量的应用
WO2022018729A1 (en) * 2020-07-20 2022-01-27 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions
CN112076217A (zh) * 2020-10-26 2020-12-15 重庆医科大学附属第一医院 一种间充质干细胞来源的抗炎症氧化脂质组合物的制备方法
WO2022104069A1 (en) 2020-11-13 2022-05-19 Advanced Therapeutic Lab, Inc. Therapeutic methods and compositions utilizing stromal vascular fraction derived from adipose tissue
US20260048085A1 (en) * 2022-08-11 2026-02-19 Boehringer Ingelheim Vetmedica Gmbh Mesenchymal stem cells for use in the treatment of insect-bite hypersensitivity in equines
CN117398450B (zh) * 2023-10-31 2025-03-11 北京三有利和泽生物科技有限公司 过表达肝细胞生长因子的间充质干细胞在制备哮喘药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010696A (en) * 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5843425A (en) * 1992-02-19 1998-12-01 The General Hospital Corporation Transplantation and graft-versus-host-disease
WO1993018648A1 (en) * 1992-03-23 1993-09-30 Baxter International Inc. In vitro-derived human neutrophil precursor cells
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US6077987A (en) * 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
PT1062321E (pt) * 1998-03-13 2005-05-31 Osiris Therapeutics Inc Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
EP1066052B1 (en) * 1998-03-18 2006-02-01 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US6797269B2 (en) * 1998-04-03 2004-09-28 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US6835377B2 (en) * 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
BR9912662A (pt) * 1998-07-31 2001-06-05 Genzyme Corp Melhoria de função cardìaca por transplante de célula de ramo mesenquimal
AU2001278010A1 (en) * 2000-07-26 2002-02-05 Scimed Life Systems, Inc. Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
US20020045260A1 (en) * 2000-10-17 2002-04-18 Shih-Chieh Hung Method of isolating mesenchymal stem cells
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
US20050158397A1 (en) * 2002-01-14 2005-07-21 Michael Chopp Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors
US6974991B2 (en) * 2003-10-29 2005-12-13 International Business Machines Corp. DRAM cell with buried collar and self-aligned buried strap
WO2005093044A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
JP4326462B2 (ja) * 2004-11-19 2009-09-09 富士通株式会社 半導体集積回路の設計を支援する設計支援装置、設計支援プログラム、及び設計支援方法
WO2006112365A1 (ja) * 2005-04-14 2006-10-26 Japan Health Sciences Foundation 間葉系幹細胞を用いる肺気腫の治療
TWM290409U (en) * 2005-10-14 2006-05-11 Ming Shiau Retractable barbeque rack
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
WO2007124594A1 (en) * 2006-04-27 2007-11-08 Cell Therapy Technologies, Inc. Et Al. Stem cells for treating lung diseases
CA2674028C (en) 2008-07-25 2012-09-04 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Recombinant b. pseudomallei adhesin protein and methods and uses thereof

Also Published As

Publication number Publication date
JP5961220B2 (ja) 2016-08-02
DK2123747T3 (en) 2016-07-04
CN101626772A (zh) 2010-01-13
EP4438721A3 (en) 2025-04-02
KR20220018084A (ko) 2022-02-14
ES2988291T3 (es) 2024-11-20
CA2637157A1 (en) 2008-09-21
EP3973970B1 (en) 2024-08-28
KR102519603B1 (ko) 2023-04-10
KR20220166876A (ko) 2022-12-19
KR20160027230A (ko) 2016-03-09
WO2008116157A3 (en) 2009-03-19
EP3653217B1 (en) 2021-09-08
JP2014224117A (ja) 2014-12-04
BRPI0802241A2 (pt) 2011-08-30
EP3095450A1 (en) 2016-11-23
EP2123747A1 (en) 2009-11-25
US20090220464A1 (en) 2009-09-03
EP3653217A1 (en) 2020-05-20
ES2891574T3 (es) 2022-01-28
CA2637157C (en) 2021-11-23
HK1136601A1 (en) 2010-07-02
KR20090122415A (ko) 2009-11-30
EP3973970A1 (en) 2022-03-30
KR20190031346A (ko) 2019-03-25
WO2008116157A2 (en) 2008-09-25
EP4438721A2 (en) 2024-10-02
KR20240008404A (ko) 2024-01-18
EP3095450B1 (en) 2019-10-23
ES2765650T3 (es) 2020-06-10
JP2010522212A (ja) 2010-07-01
US20080095749A1 (en) 2008-04-24
US20100330048A1 (en) 2010-12-30
EP2123747B1 (en) 2016-06-08
KR102357942B1 (ko) 2022-02-03
EP2051718A2 (en) 2009-04-29
KR20250052468A (ko) 2025-04-18

Similar Documents

Publication Publication Date Title
CA2637157C (en) Mesenchymal stem cells and uses therefor
US10716814B2 (en) Mesenchymal stem cells and uses therefor
HK40114915A (en) Mesenchymal stem cells and uses therefor
HK40069670A (en) Mesenchymal stem cells for use in treating idiopathic pulmonary fibrosis
HK40025518A (en) Mesenchymal stem cells for use in improving pulmonary function
HK40025518B (en) Mesenchymal stem cells for use in improving pulmonary function
HK1229734A1 (en) Mesenchymal stem cells for use in improving pulmonary function

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211012

EEER Examination request

Effective date: 20211012

EEER Examination request

Effective date: 20211012

EEER Examination request

Effective date: 20211012

EEER Examination request

Effective date: 20211012

EEER Examination request

Effective date: 20211012

EEER Examination request

Effective date: 20211012

EEER Examination request

Effective date: 20211012

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20241031

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250123